Skip to main content
Top
Published in: Pediatric Rheumatology 1/2018

Open Access 01-12-2018 | Research article

Inpatient burden of juvenile dermatomyositis among children in the United States

Authors: Michael C. Kwa, Jonathan I. Silverberg, Kaveh Ardalan

Published in: Pediatric Rheumatology | Issue 1/2018

Login to get access

Abstract

Background

Juvenile dermatomyositis (JDM) is a rare autoimmune disease that causes significant morbidity and quality of life impairment. Little is known about the inpatient burden of JDM in the US. Our goal was to determine the prevalence and risk factors for hospitalization with juvenile dermatomyositis and assess inpatient burden of JDM.

Methods

Data on 14,401,668 pediatric hospitalizations from the 2002–2012 Nationwide Inpatient Sample (NIS) was analyzed. ICD-9-CM coding was used to identify hospitalizations with a diagnosis of JDM.

Results

There were 909 and 495 weighted admissions with a primary or secondary diagnosis of JDM, respectively. In multivariable logistic regression models with stepwise selection, female sex (logistic regression; adjusted odds ratio [95% confidence interval]) (2.22 [2.05–2.42]), non-winter season (fall: 1.18[1.06–1.33]; spring (1.13 [1.01–1.27]; summer (1.53 [1.37–1.71]), non-Medicaid administered government insurance coverage (2.59 [2.26–2.97]), and multiple chronic conditions (2–5: 1.41[1.30–1.54]; 6+: 1.24[1.00–1.52]) were all associated with higher rates of hospitalization for JDM. The weighted total length of stay (LOS) and inflation-adjusted cost of care for patients with a primary inpatient diagnosis of JDM was 19,159 days and $49,339,995 with geometric means [95% CI] of 2.50 [2.27–2.76] days and $7350 [$6228–$8674], respectively. Costs of hospitalization in primary JDM and length of stay and cost in secondary JDM were significantly higher compared to those without JDM. Notably, race/ethnicity was associated with increased LOS (log-linear regression; adjusted beta [95% confidence interval]) (Hispanic: 0.28 [0.14–0.41]; other non-white: 0.59 [0.31–0.86]) and cost of care (Hispanic: 0.30 [0.05–0.55]).

Conclusion

JDM contributes to both increased length of hospitalization and inpatient cost of care. Non-Medicaid government insurance was associated with higher rates of hospitalization for JDM while Hispanic and other non-white racial/ethnic groups demonstrated increased LOS and cost of care.
Literature
1.
go back to reference Brown V, Pilkington C, Feldman B, Davidson J. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology. 2006;45(8):990–3.CrossRef Brown V, Pilkington C, Feldman B, Davidson J. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology. 2006;45(8):990–3.CrossRef
2.
go back to reference Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases registry. Arthritis Care Res (Hoboken). 2003;49(3):300–5.CrossRef Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases registry. Arthritis Care Res (Hoboken). 2003;49(3):300–5.CrossRef
3.
go back to reference Huber AM, Lang B, LeBlanc C, Birdi N, Bolaria RK, Malleson P, et al. Medium-and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43(3):541–9.CrossRef Huber AM, Lang B, LeBlanc C, Birdi N, Bolaria RK, Malleson P, et al. Medium-and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43(3):541–9.CrossRef
4.
go back to reference Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63–72.CrossRef Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63–72.CrossRef
5.
go back to reference Klein-Gitelman MS, Waters T, Pachman LM. The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2000;13(6):360–8.CrossRef Klein-Gitelman MS, Waters T, Pachman LM. The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2000;13(6):360–8.CrossRef
6.
go back to reference Kwa MC, Ardalan K, Laumann AE, Silverberg JI. Predictors of hospitalization. Arthritis Care Res (Hoboken): Length of Stay and Costs of Care Among Adults with Dermatomyositis in the United States; 2017. Kwa MC, Ardalan K, Laumann AE, Silverberg JI. Predictors of hospitalization. Arthritis Care Res (Hoboken): Length of Stay and Costs of Care Among Adults with Dermatomyositis in the United States; 2017.
7.
go back to reference Gidman W, Meacock R, Symmons D. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication. Curr Rheumatol Rep. 2015;17(5):31.CrossRef Gidman W, Meacock R, Symmons D. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication. Curr Rheumatol Rep. 2015;17(5):31.CrossRef
8.
go back to reference Boan AD, Feng WW, Ovbiagele B, Bachman DL, Ellis C, Adams RJ, et al. Persistent racial disparity in stroke hospitalization and economic impact in young adults in the buckle of stroke belt. Stroke. 2014;45(7):1932–8.CrossRef Boan AD, Feng WW, Ovbiagele B, Bachman DL, Ellis C, Adams RJ, et al. Persistent racial disparity in stroke hospitalization and economic impact in young adults in the buckle of stroke belt. Stroke. 2014;45(7):1932–8.CrossRef
9.
go back to reference Mochari-Greenberger H, Mosca L. Racial/ethnic differences in medication uptake and clinical outcomes among hospitalized cardiovascular patients with hypertension and diabetes. Am J Hypertens. 2014;28(1):106–12.CrossRef Mochari-Greenberger H, Mosca L. Racial/ethnic differences in medication uptake and clinical outcomes among hospitalized cardiovascular patients with hypertension and diabetes. Am J Hypertens. 2014;28(1):106–12.CrossRef
10.
go back to reference Curtis LM, Wolf MS, Weiss KB, Grammer LC. The impact of health literacy and socioeconomic status on asthma disparities. J Asthma. 2012;49(2):178–83.CrossRef Curtis LM, Wolf MS, Weiss KB, Grammer LC. The impact of health literacy and socioeconomic status on asthma disparities. J Asthma. 2012;49(2):178–83.CrossRef
11.
go back to reference Iwane MK, Chaves SS, Szilagyi PG, Edwards KM, Hall CB, Staat MA, et al. Disparities between black and white children in hospitalizations associated with acute respiratory illness and laboratory-confirmed influenza and respiratory syncytial virus in 3 US counties—2002–2009. Am J Epidemiol. 2013;177(7):656–65.CrossRef Iwane MK, Chaves SS, Szilagyi PG, Edwards KM, Hall CB, Staat MA, et al. Disparities between black and white children in hospitalizations associated with acute respiratory illness and laboratory-confirmed influenza and respiratory syncytial virus in 3 US counties—2002–2009. Am J Epidemiol. 2013;177(7):656–65.CrossRef
12.
go back to reference Hsu D, Brieva J, Silverberg JI. Costs of care for hospitalization for pemphigus in the United States. JAMA Dermatol. 2016;152(6):645–54.CrossRef Hsu D, Brieva J, Silverberg JI. Costs of care for hospitalization for pemphigus in the United States. JAMA Dermatol. 2016;152(6):645–54.CrossRef
13.
go back to reference Kwa MC, Ardalan K, Laumann AE, Nardone B, West DP, Silverberg JI. Validation of international classification of disease codes for the epidemiological study of dermatomyositis. Arthritis Care Res (Hoboken). 2016. Kwa MC, Ardalan K, Laumann AE, Nardone B, West DP, Silverberg JI. Validation of international classification of disease codes for the epidemiological study of dermatomyositis. Arthritis Care Res (Hoboken). 2016.
14.
go back to reference Statistics USDoLBoL. CPI detailed report June 2015. Statistics USDoLBoL. CPI detailed report June 2015.
16.
go back to reference Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol. 1998;25(6):1198–204.PubMed Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol. 1998;25(6):1198–204.PubMed
17.
go back to reference Gowdie PJ, Allen RC, Kornberg AJ, Akikusa JD. Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis. 2013;16(5):561–7.CrossRef Gowdie PJ, Allen RC, Kornberg AJ, Akikusa JD. Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis. 2013;16(5):561–7.CrossRef
18.
go back to reference Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases research registry. Arthritis Care Res (Hoboken). 2005;53(2):166–72.CrossRef Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases research registry. Arthritis Care Res (Hoboken). 2005;53(2):166–72.CrossRef
19.
go back to reference Massa M, Costouros N, Mazzoli F, De Benedetti F, La Cava A, Le T, et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 2002;46(11):3015–25.CrossRef Massa M, Costouros N, Mazzoli F, De Benedetti F, La Cava A, Le T, et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 2002;46(11):3015–25.CrossRef
20.
go back to reference Martini A, Ravelli A, Albani S, Viola S, Scotta MS, Magrini U, et al. Recurrent juvenile dermatomyositis and cutaneous necrotizing arteritis with molecular mimicry between streptococcal type 5 M protein and human skeletal myosin. J Pediatr. 1992;121(5):739–42.CrossRef Martini A, Ravelli A, Albani S, Viola S, Scotta MS, Magrini U, et al. Recurrent juvenile dermatomyositis and cutaneous necrotizing arteritis with molecular mimicry between streptococcal type 5 M protein and human skeletal myosin. J Pediatr. 1992;121(5):739–42.CrossRef
21.
go back to reference Moore EC, Cohen F, Douglas SD, Gutta V. Staphylococcal infections in childhood dermatomyositis--association with the development of calcinosis, raised IgE concentrations and granulocyte chemotactic defect. Ann Rheum Dis. 1992;51(3):378.CrossRef Moore EC, Cohen F, Douglas SD, Gutta V. Staphylococcal infections in childhood dermatomyositis--association with the development of calcinosis, raised IgE concentrations and granulocyte chemotactic defect. Ann Rheum Dis. 1992;51(3):378.CrossRef
22.
go back to reference Silverberg JI, Kwa L, Kwa MC, Laumann AE, Ardalan K. Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. Rheumatology. 2018;57(4):694–702.CrossRef Silverberg JI, Kwa L, Kwa MC, Laumann AE, Ardalan K. Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. Rheumatology. 2018;57(4):694–702.CrossRef
23.
go back to reference Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505–11.CrossRef Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505–11.CrossRef
24.
go back to reference McCann L, Juggins A, Maillard S, Wedderburn L, Davidson J, Murray K, et al. The juvenile dermatomyositis National Registry and repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatology. 2006;45(10):1255–60.CrossRef McCann L, Juggins A, Maillard S, Wedderburn L, Davidson J, Murray K, et al. The juvenile dermatomyositis National Registry and repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatology. 2006;45(10):1255–60.CrossRef
25.
go back to reference Sun C, Lee J-H, Yang Y-H, Yu H-H, Wang L-C, Lin Y-T, et al. Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. Pediatr Neonatol. 2015;56(1):31–9.CrossRef Sun C, Lee J-H, Yang Y-H, Yu H-H, Wang L-C, Lin Y-T, et al. Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. Pediatr Neonatol. 2015;56(1):31–9.CrossRef
26.
go back to reference Rider LG, Wu L, Mamyrova G, Targoff IN, Miller FW. Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology. 2010;49(12):2381–90.CrossRef Rider LG, Wu L, Mamyrova G, Targoff IN, Miller FW. Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology. 2010;49(12):2381–90.CrossRef
27.
go back to reference Shah M, Targoff IN, Rice MM, Miller FW, Rider LG. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum. 2013;65(7):1934–41.CrossRef Shah M, Targoff IN, Rice MM, Miller FW, Rider LG. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum. 2013;65(7):1934–41.CrossRef
28.
go back to reference Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–40.CrossRef Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–40.CrossRef
29.
go back to reference Henrickson M. Policy challenges for the pediatric rheumatology workforce: Part I. Education and economics. Pediatr Rheumatol Online J. 2011;9(1):23.CrossRef Henrickson M. Policy challenges for the pediatric rheumatology workforce: Part I. Education and economics. Pediatr Rheumatol Online J. 2011;9(1):23.CrossRef
30.
go back to reference Jewett EA, Anderson MR, Gilchrist GS. The pediatric subspecialty workforce: public policy and forces for change. Pediatrics. 2005;116(5):1192–202.CrossRef Jewett EA, Anderson MR, Gilchrist GS. The pediatric subspecialty workforce: public policy and forces for change. Pediatrics. 2005;116(5):1192–202.CrossRef
31.
go back to reference Hsu DY, Gordon K, Silverberg JI. The inpatient burden of psoriasis in the United States. J Am Acad Dermatol. 2016. Hsu DY, Gordon K, Silverberg JI. The inpatient burden of psoriasis in the United States. J Am Acad Dermatol. 2016.
32.
go back to reference Reed AM, Stirling JD. Association of the HLA-DQA1∗ 0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol. 1995;44(3):131–5.CrossRef Reed AM, Stirling JD. Association of the HLA-DQA1∗ 0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol. 1995;44(3):131–5.CrossRef
33.
go back to reference Wedderburn L, McHugh NJ, Chinoy H, Cooper R, Salway F, Ollier W, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis–scleroderma overlap. Rheumatology. 2007;46(12):1786–91.CrossRef Wedderburn L, McHugh NJ, Chinoy H, Cooper R, Salway F, Ollier W, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis–scleroderma overlap. Rheumatology. 2007;46(12):1786–91.CrossRef
34.
go back to reference Phillippi K, Hoeltzel M, Robinson AB, Kim S. Investigators RRACLR. Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. J Pediatr. 2017;184:38–44. e1.CrossRef Phillippi K, Hoeltzel M, Robinson AB, Kim S. Investigators RRACLR. Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. J Pediatr. 2017;184:38–44. e1.CrossRef
Metadata
Title
Inpatient burden of juvenile dermatomyositis among children in the United States
Authors
Michael C. Kwa
Jonathan I. Silverberg
Kaveh Ardalan
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2018
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-018-0286-1

Other articles of this Issue 1/2018

Pediatric Rheumatology 1/2018 Go to the issue